Skip to content

Study · Animal study (in vivo) · mouse and rat · 2025

12 results

Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.

Gabery S, Glendorf T, Ballarin-Gonzalez B, Pedersen K, Kruse T, Raun K, Kuhre RE

Life sciences6 Jul 2025Cited by 1 (Europe PMC)

PMID40628316 (opens in a new tab)DOI10.1016/j.lfs.2025.123845 (opens in a new tab)PepBankPUB-40628316
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In normal weight rats, acute cagrilintide (0833) reduced food intake dose-dependently, to a similar degree as the tool compound 0839.

    In plain wordsIn rats, cagrilintide lowered food intake as the dose rose, about as much as the tool compound 0839.

    Peptide
    Cagrilintide
    Outcome
    DecreaseFood intake after acute administration
    Study

    ratn: not reported in source

    Normal weight rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Acute administration of 0839 and 0833 to normal weight rats' dose-dependently reduced food intake to a similar degree.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In DIO mice, sub-chronic cagrilintide had a small and transient reducing effect on food intake, comparable to 0839.

    In plain wordsIn obese mice, cagrilintide briefly lowered food intake a little, similar to the tool compound 0839.

    Peptide
    Cagrilintide
    Outcome
    DecreaseFood intake after sub-chronic administration
    Study

    mousen: not reported in source

    Diet-induced obese (DIO) mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · sub-chronicAs given in this study (mouse).

    Source sentences

    Summary
    Sub-chronically, 0839 and 0833 had comparable small and transient reducing effects on food intake and body weight in DIO mice, with similar additional add-on effects on top of semaglutide.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In DIO mice, sub-chronic cagrilintide had a small and transient reducing effect on body weight, comparable to 0839.

    In plain wordsIn obese mice, cagrilintide briefly lowered body weight a little, similar to the tool compound 0839.

    Peptide
    Cagrilintide
    Outcome
    DecreaseBody weight after sub-chronic administration
    Study

    mousen: not reported in source

    Diet-induced obese (DIO) mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · sub-chronicAs given in this study (mouse).

    Source sentences

    Summary
    Sub-chronically, 0839 and 0833 had comparable small and transient reducing effects on food intake and body weight in DIO mice, with similar additional add-on effects on top of semaglutide.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In DIO mice, cagrilintide had additional add-on effects on top of semaglutide, similar to those of 0839.

    In plain wordsIn obese mice, cagrilintide added further effects on top of semaglutide, similar to the tool compound 0839.

    Peptide
    Cagrilintide
    Outcome
    DecreaseAdd-on effect to semaglutide
    Study

    mousen: not reported in source

    Diet-induced obese (DIO) mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · sub-chronicAs given in this study (mouse).

    Source sentences

    Summary
    with similar additional add-on effects on top of semaglutide.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In DIO rats, sub-chronic cagrilintide profoundly reduced food intake, as did 0839.

    In plain wordsIn obese rats, cagrilintide strongly lowered food intake, as did the tool compound 0839.

    Peptide
    Cagrilintide
    Outcome
    DecreaseFood intake in DIO rats
    Study

    ratn: not reported in source

    Diet-induced obese (DIO) rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · sub-chronicAs given in this study (rat).

    Source sentences

    Summary
    In DIO rats, sub-chronic administration of 0833 and 0839 profoundly reduced food intake and body weight, and both potentiated semaglutide's effects on food intake and body weight to an equal extended.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In DIO rats, sub-chronic cagrilintide profoundly reduced body weight, as did 0839.

    In plain wordsIn obese rats, cagrilintide strongly lowered body weight, as did the tool compound 0839.

    Peptide
    Cagrilintide
    Outcome
    DecreaseBody weight in DIO rats
    Study

    ratn: not reported in source

    Diet-induced obese (DIO) rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · sub-chronicAs given in this study (rat).

    Source sentences

    Summary
    In DIO rats, sub-chronic administration of 0833 and 0839 profoundly reduced food intake and body weight, and both potentiated semaglutide's effects on food intake and body weight to an equal extended.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In DIO rats, cagrilintide potentiated the effect of semaglutide on food intake, equally to 0839.

    In plain wordsIn obese rats, cagrilintide boosted the food-intake effect of semaglutide, as much as the tool compound 0839.

    Peptide
    Cagrilintide
    Outcome
    DecreasePotentiation of semaglutide effect on food intake
    Study

    ratn: not reported in source

    Diet-induced obese (DIO) rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · sub-chronicAs given in this study (rat).

    Source sentences

    Summary
    In DIO rats, sub-chronic administration of 0833 and 0839 profoundly reduced food intake and body weight, and both potentiated semaglutide's effects on food intake and body weight to an equal extended.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In DIO rats, cagrilintide potentiated the effect of semaglutide on body weight, equally to 0839.

    In plain wordsIn obese rats, cagrilintide boosted the body-weight effect of semaglutide, as much as the tool compound 0839.

    Peptide
    Cagrilintide
    Outcome
    DecreasePotentiation of semaglutide effect on body weight
    Study

    ratn: not reported in source

    Diet-induced obese (DIO) rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · sub-chronicAs given in this study (rat).

    Source sentences

    Summary
    In DIO rats, sub-chronic administration of 0833 and 0839 profoundly reduced food intake and body weight, and both potentiated semaglutide's effects on food intake and body weight to an equal extended.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    Cagrilintide mainly reduced body weight by fat mass reduction, as did 0839.

    In plain wordsIn animal tests, cagrilintide lowered body weight mainly by reducing fat mass, as did the tool compound 0839.

    Peptide
    Cagrilintide
    Outcome
    DecreaseFat mass
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both compounds mainly reduced body weight by fat mass reduction and equally improved metabolic parameters.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    Cagrilintide improved metabolic parameters equally to 0839; the parameters are not named in the abstract.

    In plain wordsIn animal tests, cagrilintide improved metabolic measures, equally to the tool compound 0839.

    Peptide
    Cagrilintide
    Outcome
    Direction not reportedMetabolic parameters
    Study

    n: not reported in source

    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both compounds mainly reduced body weight by fat mass reduction and equally improved metabolic parameters.

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 11AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Efficacy outcome

    In diet-induced obese mice, the amylin analogues 0839 and 0833 each had similar small, transient additional effects on food intake and body weight when added on top of semaglutide.

    In plain wordsIn mice, adding an amylin drug to semaglutide gave small, short-lived extra reductions in food intake and body weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseFood intake and body weight, amylin analogue added to semaglutide in DIO mice
    Study

    mousen: not reported in source

    diet-induced obese (DIO) mice
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Sub-chronically, 0839 and 0833 had comparable small and transient reducing effects on food intake and body weight in DIO mice, with similar additional add-on effects on top of semaglutide.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 12AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Efficacy outcome

    In diet-induced obese rats, 0833 and 0839 each potentiated the effects of semaglutide on food intake and body weight to an equal extent.

    In plain wordsIn rats, adding an amylin drug to semaglutide increased the reduction in food intake and body weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseFood intake and body weight, amylin analogue added to semaglutide in DIO rats
    Study

    ratn: not reported in source

    diet-induced obese (DIO) rats
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    In DIO rats, sub-chronic administration of 0833 and 0839 profoundly reduced food intake and body weight, and both potentiated semaglutide's effects on food intake and body weight to an equal extended.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.